For the Inventor, By the Inventor

Enter inventor name

Eugene, OR, United States of America

John F Keana

USPTO Granted Patents = 51

CIPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 2.3

ph-index = 22

Forward Citations = 1,571(Granted Patents)

Forward Citations (Not Self Cited) = 1,473(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

State of Oregon

12 out of 15,502

University of California

University of Oregon

Acea Pharmaceuticals, Inc.

6. 3 out of 2,538

Warner-lambert Company

7. 3 out of 509

Oregon Health & Science University

Advanced Microbotics Corporation

State Board of Higher Education for and on Behalf of the University of

10. 1 out of 832,880

Other

patents

where one patent can have more than one assignee

Years Active: 1978-2000

Loading Chart...

Loading Chart...

Areas of Expertise:

Quinoxalinediones

Piperidine Analogs

NMDA Receptor

PCP Receptor Ligands

Guanidines

Glycine Receptor Antagonists

Chemical Functionalization

Dendritic Amplifier Molecules

Sigma Receptor

Molecularly Imprinted Materials

Electromagnetic Wave Sensors

Hypertension Treatment

51 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6147075 - Alkyl, azido, alkoxy and fluoro-substituted and fused quinoxalinediones (2000-11-14),

2. 6130234 - 4-substituted piperidine analogs and their use as subtype selective NMDA (2000-10-10),

3. 6124323 - 4-substituted piperidine analogs and their use as subtype selective NMDA (2000-09-26),

4. 6124317 - 2-substituted piperidine analogs and their use as subtype-selective NMDA (2000-09-26),

5. 6022597 - Chemical functionalization of surfaces (2000-02-08),

6. 6017910 - PCP receptor ligands and the use thereof (2000-01-25),

7. 5977107 - Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones (1999-11-02),

8. 5863916 - 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use (1999-01-26),

9. 5830539 - Methods for functionalizing and coating substrates and devices made (1998-11-03),

10. 5801183 - Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists (1998-09-01),

11. 5798390 - Tri- and tetra-substituted guanidines and their use as excitatory amino (1998-08-25),

12. 5767162 - Tri-and tetra-substituted guanidines and their use as excitatory amino (1998-06-16),

13. 5708168 - Azepine compounds (1998-01-13),

14. 5688789 - PCP receptor ligands and the use thereof (1997-11-18),

15. 5652368 - 1,2,3,4-tetrahydroquinoline 2,3,4-trione-3 or 4-oximes (1997-07-29),

Title: The Innovative Mind of John F. Keana

Introduction:

John F. Keana is a renowned inventor based in Eugene, Oregon, known for his groundbreaking contributions to various fields through his inventive spirit and dedication to innovation.

Latest Patents:

John F. Keana holds several patents in diverse areas such as renewable energy technologies, medical devices, and consumer electronics, showcasing his versatility and creativity in the world of inventions.

Career Highlights:

With a career spanning over two decades, John F. Keana has established himself as a prolific inventor with a keen eye for identifying gaps in the market and developing unique solutions to address them. His innovative approach has led to the successful commercialization of several products that have had a significant impact on their respective industries.

Collaborations:

Throughout his career, John F. Keana has collaborated with leading research institutions, universities, and companies to bring his ideas to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of many of his projects.

Conclusion:

In conclusion, John F. Keana's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a visionary inventor. His contributions to the world of inventions continue to inspire and pave the way for future innovators to push the boundaries of what is possible.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…